Health Catalyst Appoints Simeon Kohl as CEO; Ben Albert Moves to CBO

What Happened Health Catalyst announced on Sept 8, 2026 (via Form 8-K) that Simeon Kohl will succeed Benjamin (Ben) Albert as Chief Executive Officer, President, principal executive officer and principal operating officer effective September 14, 2026, and will join the Board as a Class III director. Ben Albert resigned as CEO and director effective September 13, 2026 and will become the Company’s Chief Business Officer effective September 14, 2026. The company filed offer letters and related agreements for both executives and issued a press release announcing the changes.

Key Details

• Simeon Kohl compensation: base salary $600,000; annual bonus target 100% of base salary; participation in Executive Severance Plan as a Tier 1 Executive; expected grant of 2,747,385 RSUs (915,975 RSUs vest Sept 4, 2027; remainder vest in eight roughly equal quarterly installments).
• Benjamin Albert compensation as Chief Business Officer: base salary $415,000; prorated 2026 bonus calculation described in offer letter; beginning Jan 1, 2027 his annual bonus target will be 60% of base salary; continues in Executive Severance Plan as a Tier 2 Executive.
• Board adopted the Health Catalyst 2026 Employment Inducement Incentive Plan on Sept 4, 2026 and reserved 2,747,385 shares for inducement awards; adopted pursuant to Nasdaq Rule 5635(c)(4) (no stockholder approval).
• The company will enter into its standard indemnification agreement with Mr. Kohl; filings include the Kohl and Albert offer letters and the Inducement Plan as exhibits.

Why It Matters This filing documents a leadership transition at the top of Health Catalyst and provides concrete compensation and equity grant details for the incoming CEO and the reconfigured role of the former CEO. Investors should note the new CEO’s pay mix (salary, bonus target, large RSU inducement) and the adoption of an inducement equity plan (2.75M shares reserved) made under Nasdaq rules — all of which can affect dilution, executive incentives and near-term corporate strategy alignment. The filing does not report any disagreement between the parties regarding company operations.